openPR Logo
Press release

OTC Cough, Cold & Allergy Medicine Market: Future Forecast Indicates Impressive Growth Rate by 2022 | Key Player are Sanofi-Aventis, Johnson & Johnson Service Inc., Reckitt Benckiser Group Plc., Novartis AG, GlaxoSmithKline Plc., etc.

11-28-2018 02:03 PM CET | Health & Medicine

Press release from: Fact.MR

OTC Cough, Cold & Allergy Medicine Market: Future Forecast

An up-to-date research report has been disclosed by Fact.MR highlighting the titled “OTC Cough, Cold & Allergy Medicine Market: Future Forecast Indicates Impressive Growth Rate by 2022” which delivers an outlook of current market value as well as the expected forecast including Rate on Investment (ROI) together with growing CAGR of 4.9% during 2017-2022. The report studies the OTC Cough Cold & Allergy Medicine Market Worldwide, especially in North America, Europe, Southeast Asia, India and Other Regions with production, size, growth, revenue, consumption, import and export in these regions.

Request 100 Page Sample Report from Here - https://www.factmr.com/connectus/sample?flag=S&rep_id=71

Very few individuals consult doctors for common conditions such as cold, cough and allergies; most of them opt for OTC medicines instead.  In the view of such prominent practices, the global sales of the OTC cough, cold and allergy medicines have remained propped up for the past decade or so. Cough, cold and allergy medicines are one of most common OTC (over-the-counter) categories, however, physicians recommend their use only for minor health issues. In many countries, there are certain laws enforced on directs sales of these medicines in order to ensure consumer safety.  In addition, these medicines offer extreme convenience to a modern consumer, living a fast-paced life. The aforementioned factors are expected to reflect favorably on the global OTC cough, cold and allergy medicines market over the next five years. Moreover, an increasing number of immunosuppressed individuals and rising global geriatric population is also expected to further drive the demand OTC medicines for cough, cold and allergy.  The recent study conducted by Fact.MR reveals that the global OTC cough, cold and allergy medicine market is poised to increase at a CAGR of 4.9% during 2017 to 2022 to reach a valuation of around US$ 37,300 Mn.

Asia-Pacific excluding Japan (APEJ) to Remain the Largest Market for OTC Cough, Cold and Allergy Medicines

Asia-Pacific excluding Japan (APEJ) is projected to remain the most lucrative market for OTC cough, cold and allergy medicines throughout the forecast period. In terms of revenue, APEJ is anticipated to account for an impressive share of the global market in 2017 and beyond. The region’s proximity to air pollution has led to the rise in prevalence of various respiratory disorders. Moreover, acceptance rate of OTC medicines is extremely high in the region owing to their low cost and convenience of purchase.

By drug type, antihistamine is projected to account for more than one-third share of the market in terms of revenue by 2017-end. Antihistamines drugs reduce the release of histamine from histamine-1 receptors and are commonly used for treating allergic reactions such as inflammation (redness), swelling (edema), watery eyes or runny nose and sneezing.

To View Full Global Market Research Report Click Here - https://www.factmr.com/report/71/otc-cough-cold-allergy-medicine-market

Pharmacies will remain the leading OTC channel for sales of cough, cold and allergy medicines during the assessment period.  Meanwhile, drug store OTC channel segment is expected to account for the second largest revenue share of the market by 2017-end.

By dosage, the tablet segment is estimated to account for more than 33% revenue share of the market and is expected to reach a valuation of around US$ 12,400 Mn towards the end of the forecast period.

Competition Tracking

Key companies profiled in Fact.MR’s report include Sanofi-Aventis, Johnson & Johnson Service, Inc., Reckitt Benckiser Group Plc., Novartis AG, GlaxoSmithKline Plc., AstraZaneca Plc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Prestige Brands Holdings, Inc., Procter & Gamble Co., Bristol-Myers Squib Co., Merck & Co., and Allergen. Many of these market players are actively focusing on increasing their market presence and development of more efficient products.

Table of Content:

Global OTC Cough, Cold and Allergy Medicines Market - Executive Summary
Global OTC Cough, Cold and Allergy Medicines Market Overview
2.1. Introduction

       2.1.1. Global OTC Cough, Cold and Allergy Medicines Market Taxonomy

       2.1.2. Global OTC Cough, Cold and Allergy Medicines Market Definition

2.2. Global OTC Cough, Cold and Allergy Medicines Market Size (US$ Mn) and Forecast, 2012-2022

       2.2.1. Global OTC Cough, Cold and Allergy Medicines Market Y-o-Y Growth

2.3. Global OTC Cough, Cold and Allergy Medicines Market Dynamics

       2.3.1. Drivers

       2.3.2. Restraints

       2.3.3. Trends

Continued…………………………..

Buy Useful Figures about Global Market Report from Here - https://www.factmr.com/checkout/71/S

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us

Fact.MR
11140 Rockville Pike
Suite 400, Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Blog: https://factmrblog.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release OTC Cough, Cold & Allergy Medicine Market: Future Forecast Indicates Impressive Growth Rate by 2022 | Key Player are Sanofi-Aventis, Johnson & Johnson Service Inc., Reckitt Benckiser Group Plc., Novartis AG, GlaxoSmithKline Plc., etc. here

News-ID: 1405365 • Views:

More Releases from Fact.MR

Industrial Vacuum Cleaner Market Outlook CAGR of 5% Expected by 2033
Industrial Vacuum Cleaner Market Outlook CAGR of 5% Expected by 2033
The global Industrial Vacuum Cleaner Market (産業用掃除機市場) is projected to reach a value of US$ 1.65 billion by 2033, with a forecasted Compound Annual Growth Rate (CAGR) of 5% over the next decade. Industrial vacuum cleaners operate similarly to conventional cleaners by using motor-driven fans to create suction, drawing in dust particles into attached dust bags. However, they excel in wet cleaning, offering options for water-based cleaning on various surfaces.
Insomnia Treatment Market Expected to Grow at 5.2% CAGR from 2024 to 2034
04-25-2024 | Health & Medicine
Fact.MR
Insomnia Treatment Market Expected to Grow at 5.2% CAGR from 2024 to 2034
The global insomnia treatment market (不眠症治療市場) is projected to reach a value of US$ 6,886.1 million by 2024 and is expected to grow at a CAGR of 5.2% from 2024 to 2034, reaching US$ 11,385.5 million in 2034. A key driver of this growth is the increasing awareness and understanding of insomnia among patients and healthcare professionals. Insomnia is a prevalent sleep disorder affecting millions worldwide, driving the demand for
Natural Flavor Carrier Market Share, Trend and Forecast to 2028
04-25-2024 | Food & Beverage
Fact.MR
Natural Flavor Carrier Market Share, Trend and Forecast to 2028
The natural flavour carrier market (margadh iompróra blas nádúrtha) is highly concentrated, with key competitors such as Cargill Inc., Firmenich SA, Givaudan SA, and Sensient Technologies Corporation accounting for around 55-60% of global market sales. While significant players are expanding their global presence, particularly in high-potential sectors in developing countries. Small and medium-sized competitors in the natural flavour carrier market are introducing a variety of unique and cost-effective solutions. Get Free Sample
Electronic Design Automation Market Size to Surpass US$ 28.6 billion by 2032, at 7.8% CAGR
Electronic Design Automation Market Size to Surpass US$ 28.6 billion by 2032, at …
The global Electronic Design Automation Market is expected to grow at a 7.8% CAGR to a US value of $28.6 billion by the end of 2032. Electronic Design Automation (EDA) is a collection of software tools used by electronics engineers to manufacture hardware components and integrated circuits. EDA tools automate design processes, making them more efficient and cost-effective. They manage the complexity of current designs by providing capabilities such as simulation

All 5 Releases


More Releases for OTC

Deadline on Nov. 9th upcoming in Lawsuit for Investors in Harborside Inc. (OTC: …
The Shareholders Foundation announced that a deadline is coming up on November 9, 2020 in the lawsuit filed for certain investors of Harborside Inc. (OTC: HSDEF, OTC: HBORF). Investors who purchased shares of Harborside Inc. (OTC: HSDEF, OTC: HBORF) have certain options and there are strict and short deadlines running. Deadline: November 9, 2020. Harborside Inc. stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to
Investigation for Long-Term Investors in shares of Volkswagen AG (OTC: VWAGY / O …
An investigation on behalf of current long-term investors in shares of Volkswagen AG (OTC: VWAGY / OTC: VLKAF / OTC: VWAPY) was announced over potential breaches of fiduciary duties by certain officers and directors at Volkswagen AG. Investors who purchased shares of Volkswagen AG (OTC: VWAGY / OTC: VLKAF / OTC: VWAPY) and currently hold any of those Volkswagen AG shares have certain options and should contact the Shareholders Foundation at
OTC: VWAGY / OTC: VLKAF / OTC: VWAPY Shareholder Notice: Update in Lawsuit again …
The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Volkswagen AG (OTC: VWAGY) (OTC: VWAPY) shares. Investors, who purchased shares of Volkswagen AG (OTC: VWAGY) (OTC: VLKAF) (OTC: VWAPY), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. On September 25, 2015, a lawsuit was filed against Volkswagen AG (alleged securities laws violations. The plaintiff claimed that the defendants
OTC Analgesics Market OTC analgesics market is projected to register a steady ex …
About OTC Analgesics Market The global OTC analgesics market is projected to register an above-average CAGR during 2017 to 2022. Global sales of OTC analgesics is estimated to account for nearly US$ 25,000 Mn revenues by 2022-end. Get Sample copy of this Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=75 The trend of using off-label drugs that are affordable and unapproved, but effective in treating diseases, has been witnessing an upsurge over the past few years.
03-14-2018 | Health & Medicine
Fact.MR
OTC Analgesics Market Report 2017-22: Pharmacy to Remain the Most Lucrative OTC …
A fresh study, covering “OTC Analgesics Market Forecast, Trend Analysis & Competition Tracking – Global Review 2017 to 2022” has been broadcasted to wide online repository of Fact MR, which presents deep focus on the healthcare market. This smart study contains precise data that offers a clear insight about market current scenario and future projections for the benefit of readers. Moreover, the study enclosed significant data which tends to make
The OTC Drugs Market: Commercial Trends and Rx-to-OTC Switch Prospects
ReportsWeb.com has announced the addition of the “Global OTC Drugs Market Research Report 2017” The report focuses on global major leading industry players with information such as company profiles, product picture and specification. GBI Research's latest report, "The OTC Drugs Market: Commercial Trends and Rx-to-OTC Switch Prospects" discusses trends in the over-the-counter (OTC) pharmaceuticals market and the commercial prospects for switching drugs from prescription-only to OTC status. The report assesses current